NCT07019675View on ClinicalTrials.gov

A Study of SKB518 in Patients With Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 20, 2027

Study Completion Date

June 20, 2027

Conditions
Lung Carcinoma
Interventions
DRUG

SKB518 for injection

SKB518 for injection is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Science, Beijing

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY